Financial Data and Key Metrics Changes - The company generated net revenue of $10 million in Q3 2024, representing a 24% increase from Q2 2024 [8] - The gross net discount for FUROSCIX was approximately 15.7%, exceeding the guided range of 10% to 15% [9] - The net loss for Q3 2024 was $35.1 million, compared to $15.6 million in Q3 2023, primarily due to one-time charges [27][28] Business Line Data and Key Metrics Changes - Approximately 3,100 unique healthcare providers prescribed FUROSCIX, a 13% increase compared to Q2 2024 [18] - The company filled approximately 10,800 doses of FUROSCIX, a 16% increase from the previous quarter, with the average number of doses per prescription rising to 6.8 [19] - The acceptance of the sNDA filing by the FDA for expanding FUROSCIX's indication to include CKD patients was a significant achievement [12] Market Data and Key Metrics Changes - The company anticipates that the GTN discount will increase to 35% by the end of 2025 due to the Medicare Part D redesign [9] - The company ended Q3 2024 with $91.5 million in cash and cash equivalents, up from $76 million at the end of 2023 [28] Company Strategy and Development Direction - The company is focused on expanding FUROSCIX's indications to cover all heart failure patients, including Class IV patients, which represent a significant portion of hospitalizations [10] - The company is preparing for a potential launch of FUROSCIX for CKD, with a PDUFA date set for March 6, 2025 [14] - The transformative financing completed in August 2024 added approximately $75 million to the balance sheet, supporting projected cash flow through expected profitability [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about growth driven by sales force expansion and indication expansion for FUROSCIX [8] - The management noted that the fourth quarter is expected to be the biggest opportunity of the year due to increased hospital admissions related to fluid overload during the holiday season [34] - Management highlighted the positive reception from nephrologists regarding FUROSCIX, indicating a strong potential for the CKD market [42] Other Important Information - The company is working on a low-volume Autoinjector, which demonstrated promising results in a PK/PD bridging study [15] - The new FUROSCIX direct patient services hub has improved the prescribing process, receiving positive feedback from healthcare providers [20] Q&A Session Summary Question: What do you think the doses per prescription could look like for FUROSCIX and CKD relative to heart failure? - Management indicated that doses for CKD would be similar to Class II and Class III heart failure patients, around 6.0 to 6.5 [31] Question: What do you think the rate of on-body diffuser versus autoinjector could shake out to in the long-term? - Management projected that over 90% of treatments would be in the autoinjector format, with some patients likely to remain on the current system [32] Question: Is there any expected seasonality that we could see in Q4? - Management confirmed that Q4 is expected to have the highest sales due to increased hospital admissions related to fluid overload during the holidays [34] Question: What percentage of prescriptions do you think will be Class IV as you exit the year? - Management noted that Class IV patients currently represent about 10% of prescriptions, with expectations for growth [38] Question: Can you comment on how the initial nephrology detailing is going? - Management reported positive reception from nephrologists, with many expressing interest in prescribing FUROSCIX [42] Question: What led to a slower end to the quarter than expected? - Management attributed the slowdown to coverage gap rebates affecting fill rates, despite continued growth in script writing [45][46] Question: What was the conversion rate in the third quarter? - The fill rate for prescriptions was 53%, an increase from 48% in Q2 [48] Question: How do you see the conversion rate going into next year with the Part D redesign? - Management projected a fill rate of 65% for next year, benefiting from the redesign and increased affordability for patients [55]

ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -23.33%. A quarter ago, it was expected that this company would post a loss of $0.44 per share when it actually produced a loss of $0.44, delivering no surprise.Over the last four quarters, the company has surpasse ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share SCPH The Nasdaq Global Select Market Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIE ...

Exhibit 99.1 Pharmaceutica Powered by passion. Driven by patient care. scPharmaceuticals Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million transformative financing in a combination of debt and ...

Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million transformative financing in a combination of debt and equity that is anticipated to fund the Company through expected profitability Company to host investor conference call and webcast today, Wednesday, November 13th, at ...

BURLINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, November 13, 2024, to discuss the financial results for the third quarter 2024 and provide a business update. Participants should dial 1-877-407-9208 (domestic) or 1-201-493-6784 ( ...

scPharmaceuticals, Inc. (SCPH) closed the last trading session at $5.06, gaining 12.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $19.83 indicates a 291.9% upside potential. The mean estimate comprises six short-term price targets with a standard deviation of $2.99. While the lowest estimate of $16 indicates a 216.2% increase from the current price level, the most optimistic a ...

scPharmaceuticals Inc. (NASDAQ:SCPH) Q2 2024 Earnings Call Transcript August 14, 2024 4:30 PM ET Company Participants PJ Kelleher - IR John Tucker - CEO Steve Parsons - SVP, Commercial Rachael Nokes - CFO Conference Call Participants Roanna Ruiz - Leerink Partners Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, and welcome to the scPharmaceuticals Second Quarter 2024 Earnings Conference Call. At this time all participants are in a listen-only mode. A brief question-and-answer session wi ...

ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.44 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.36 per share a year ago. These figures are adjusted for nonrecurring items. A quarter ago, it was expected that this company would post a loss of $0.45 per share when it actually produced a loss of $0.36, delivering a surprise of 20%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. scPharmaceuticals, which belongs to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.0001 per share SCPH The Nasdaq Global Select Market Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissi ...